24 completed, 11 terminated, 1 not yet recruiting. 12 Phase 4, 9 Phase 3, 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 12 | Completed 8, Terminated 4 |
| Phase 3 | 9 | Completed 5, Terminated 3, Not yet recruiting 1 |
| Phase 2 | 8 | Completed 4, Terminated 4 |
| Phase 1 | 5 | Completed 5 |
Follow Bukwang Pharmaceutical: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy Lurasidone, Placebo, Background Antidepressant Therapy - Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features | Phase 3 | Not yet recruiting | Bukwang Pharmaceutical | 364 | 2026-09-28 | 2026-09-16 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects SOL-804-F, Zytiga - Prostate Cancer | Phase 1 | Completed | Bukwang Pharmaceutical | 48 | 2023-08-10 | 2024-02-05 |
| Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components Part 1, JM-010 component Group A, Part 1, JM-010 component Group B, Part 1, JM-010 component Group C - Dyskinesias, Parkinson Disease | Phase 2 | Terminated | Bukwang Pharmaceutical | 41 | 2021-04-28 | 2024-06-17 |
| The Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Mild and Moderate COVID-19 Clevudine, Placebo - COVID-19 | Phase 2 | Completed | Bukwang Pharmaceutical | 104 | 2021-03-19 | 2022-07-22 |
| The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 Clevudine, Placebo - COVID-19 | Phase 2 | Completed | Bukwang Pharmaceutical | 64 | 2020-05-26 | 2022-07-22 |
| A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia JM-010 group A, JM-010 group B, Placebos - Dyskinesias | Phase 2 | Completed | Contera Pharma | 89 | 2019-07-22 | 2024-06-17 |
| A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia Lurasidone HCL 160 mg, Quetiapine XR 600 mg - Schizophrenia | Phase 3 | Completed | Bukwang Pharmaceutical | 210 | 2018-04-09 | 2023-02-08 |
| A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment Apatinib mesylate - Gastric Cancer | Phase 1 | Completed | Bukwang Pharmaceutical | 6 | 2016-03-01 | 2022-07-22 |
| Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia JM-010, Placebo - Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | Phase 2 | Completed | Bukwang Pharmaceutical | 30 | 2015-05-01 | 2016-01-13 |
| Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury autologous adipose tissue derived mesenchymal stem cells - Spinal Cord Injury | Phase 1 | Completed | Bukwang Pharmaceutical | 15 | 2012-04-01 | 2015-02-13 |
| A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil, Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil, Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil - Healthy | Phase 1 | Completed | Bukwang Pharmaceutical | 42 | 2012-04-01 | 2012-09-18 |
| Comparative Efficacy and Safety of Fenoverine Fenoverine, Timebutine - Irritable Bowel Syndrome | Phase 4 | Completed | Bukwang Pharmaceutical | 186 | 2011-12-01 | 2014-12-18 |
| Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy Silymarin, Placebo - Hepatitis C | Phase 3 | Completed | Bukwang Pharmaceutical | 53 | 2010-11-01 | 2013-11-25 |
| Randomized, Double-blind Study to Assess the Efficacy and Safety of α-lipoic Acid Versus BK-C-0701 in Subjects With Diabetic Neuropathy BK-C-0701 - Diabetic Neuropathies | Phase 3 | Completed | Bukwang Pharmaceutical | 164 | 2010-08-01 | 2012-04-25 |
| A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC clevudine, Adefovir - Hepatitis B Associated Hepatocellular Carcinoma | Phase 4 | Completed | Bukwang Pharmaceutical | 33 | 2010-06-01 | 2014-12-18 |
| An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B Clevudine 30mg, Clevudine 20mg+Adefovir dipivoxil 10mg, Clevudine 20mg - Chronic Hepatitis B | Phase 4 | Completed | Bukwang Pharmaceutical | 60 | 2010-03-01 | 2014-12-18 |
| A Study to Evaluate the Efficacy and the Change of sAg Levels in Chronic Hepatitis B Patients Receiving Clevudine Treatment Over the Long Period Clevudine - Chronic Hepatitis B | Phase 4 | Terminated | Bukwang Pharmaceutical | 200 | 2009-11-01 | 2015-07-22 |
| A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B Clevudine, Adefovir - Chronic Hepatitis B | Phase 4 | Terminated | Bukwang Pharmaceutical | 200 | 2009-09-01 | 2014-12-18 |
| A Study Comparing the Pharmacokinetics of BK-C-0701 320mg, 480mg and Thiocacid HR Tab 600mg in Healthy Adult Male Subjects Thiocacid HR Tab 600mg, BK-C-0701 320mg, BK-C-0701 480mg - Healthy Adult Male | Phase 1 | Completed | Bukwang Pharmaceutical | 30 | 2009-08-01 | 2010-12-13 |
| A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients Clevudine, Entecavir - Chronic Hepatitis B | Phase 4 | Terminated | Bukwang Pharmaceutical | 75 | 2009-08-01 | 2014-12-18 |
Showing 20 of 36. Sign in to see all of them.
Hepatitis B (9) · Hepatitis B, Chronic (9) · Dyskinesias (3) · COVID-19 (2) · Parkinson Disease (2) · Abdominal Pain (1) · Depressive Disorder, Major (1) · Diabetic Neuropathies (1) · Hepatitis C (1) · Irritable Bowel Syndrome (1) · Prostatic Neoplasms (1) · Schizophrenia (1) · Spinal Cord Injuries (1) · Stomach Neoplasms (1)
clevudine (22) · adefovir dipivoxil (5) · adefovir (4) · Lurasidone Hydrochloride (2) · Abiraterone Acetate (1) · Lamivudine (1) · Silymarin (1) · apatinib (1) · entecavir (1) · fenoverine (1)
South Korea (32) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · South Africa (1) · Spain (1) · United States (1)
Hyo Suk Lee, M.D., Ph.D. (3) · Hyo-Suk Lee, MD. PhD (3) · Byung Chul Yoo, MD. PhD. (1) · George KK Lau, M.D. (1) · Heon Young Lee, MD. PhD. (1) · Hyeon Woong Yang, MD. PhD. (1) · Hyo-suk Lee, MD. PhD. (1) · June Sung Lee, M.D. (1) · Jung Hee Yeon (1) · Lee Chang Don, MD, PhD (1) · Nancy Leung, M.D. (1) · SeungHwan Lee (1) · Sooyeon Park (1) · Taehyeong Jo, PhD (1)
PMID 16628625, PMID 17647293, PMID 31356217, PMID 38271925
2017 (1)